INTRODUCTION {#S1}
============

Pseudoxanthoma elasticum (PXE), the prototype of heritable ectopic mineralization disorders, is characterized by late-onset, yet progressive, calcium hydroxyapatite deposition on elastic structures in peripheral connective tissues ([@R21]; [@R39]). Clinically, PXE manifests with characteristic cutaneous, ocular and cardiovascular findings. The disease is inherited in an autosomal recessive manner with apparently complete penetrance, and *ABCC6* has been identified as the gene harboring mutations in most patients with PXE ([@R3]; [@R14]; [@R30]; [@R35]). This gene encodes ABCC6, a putative transmembrane efflux transporter protein primarily expressed in the baso-lateral plasma membranes of hepatocytes and to a lesser extent in the proximal tubules of the kidneys.

In addition to *ABCC6*, recent studies have disclosed mutations in the *ENPP1* gene in some patients with PXE-like cutaneous findings, often associated with extensive vascular mineralization ([@R11]; [@R18]). *ENPP1* mutations also underlie a severe ectopic mineralization disorder, generalized arterial calcification of infancy (GACI), an autosomal recessive disease, which affects primarily the arterial blood vessels ([@R31]; [@R32]). This disease is commonly diagnosed by pre- or perinatal ultrasound, and the affected individuals in most cases die within the first year of life from cardiovascular complications. While most cases of GACI are caused by mutations in the *ENPP1*, *ABCC6* mutations have also been demonstrated in some patients ([@R16]; [@R22]). Thus, there is considerable phenotypic and genotypic overlap between PXE and GACI ([@R20]; [@R23]).

Over 300 distinct mutations in the *ABCC6* gene have been identified in patients with PXE, two common recurrent mutations, p.R1141X and genomic deletion of exons 23 through 29 (c.2996-1724_4209-478del; referred to as del23-29), representing 18.5 and 9.9% of all reported mutant alleles, respectively ([@R25]; [@R37]; [@R40]). However, essentially all published studies have focused on PXE in Caucasian patient populations, and very few mutations have been reported in patients of Asian ancestry. In this study, we have investigated a cohort of 29 Chinese PXE patients from unrelated families, so far the largest cohort of Asian PXE patients. Genetic analysis of 22 patients revealed a mutation profile clearly distinct from that found in Caucasian patients, and the Chinese PXE patients harbor unique mutations.

RESULTS {#S2}
=======

Identification of *ABCC6* Mutations {#S3}
-----------------------------------

A cohort of 29 Chinese patients with PXE was examined, and the diagnosis was initially suggested by characteristic cutaneous lesions and histopathology using routine Hematoxylin-Eosin as well as Verhoeff van Gieson and von Kossa stains for elastic structures and mineralization, respectively ([@R38]) ([Fig. S1](#SD1){ref-type="supplementary-material"}). The majority of patients were females (26/29), most of them had the onset at less than 30 years of age, and the majority of patients (\~90%) had the disease for over 6 years since diagnosis at the time of the study ([Table S1](#SD1){ref-type="supplementary-material"}).

In a subset of 22 patients, DNA, isolated from either peripheral blood leukocytes or paraffin-embedded skin biopsies, was available and subjected to mutation analysis first using a strategy and primers that we have previously developed for streamlined mutation detection in the *ABCC6* gene ([@R12]; [@R25]). A total of 36 sequence variants in *ABCC6* were discovered. These variants included 6 small insertion or deletion mutations resulting in premature termination codon (PTC), and these variants were considered pathogenic ([Fig. 1A](#F1){ref-type="fig"}). Among the 30 single nucleotide substitutions, we identified 7 synonymous mutations while 23 were missense mutations. Among the nonsynonymous substitutions, 9 were present in the single nucleotide polymorphism (SNP) database (<http://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?geneId=368&ctg=NT_010393.16&mrna=NM_001171.5&prot=NP_001162.4&orien=forward>) in frequency \>1% and were therefore considered to be nonpathogenic polymorphisms. Among the 14 amino acid substitutions not present in the SNP database, one of them, c.3341G\>A, has been previously reported as a pathogenic mutation. The remaining 13 amino acid substitutions were examined for potential pathogenicity by PolyPhen-2 and SIFT prediction programs ([Table 1](#T1){ref-type="table"}), and 10 putative missense variants were examined for subcellular localization in mouse hepatocyte plasma membrane targeting assay and for functional pathogenicity in zebrafish mRNA rescue assay *in vivo* (see below). Among the putative pathogenic mutations, only two of them, one missense and one single-nucleotide deletion mutation, have been published previously. Most notably, none of the Chinese PXE patients had the recurrent p.R1141X or del23-29 mutation. When examined individually, 13 patients were homozygous or compound heterozygous with mutations in both alleles of *ABCC6*, while in 7 patients only one mutation was found. In the latter cases, search for ENPP1 mutations was unyielding.

Assay of membrane targeting of the mutant protein {#S4}
-------------------------------------------------

Among the discovered sequence variants, 13 of them resulted in amino acid substitution ([Table 1](#T1){ref-type="table"} and [Fig. 1B](#F1){ref-type="fig"}), and they all were initially considered pathogenic because searches of the SNP database did not report the presence of these variants or they were present in frequency of less than 1%. Analysis of the potential functional consequences of these mutations at the protein level by SIFT and PolyPhen-2 bioinformatics programs predicted that 6 of them were definitely damaging/probably disruptive while the remaining 7 were tolerated or benign ([Table 1](#T1){ref-type="table"}). In the latter group, three variants, even though not present in the SNP database, were recurrent in the Chinese families with PXE in high frequency, and they were considered nonpathogenic and not studied further.

Theoretically, missense mutations could inactivate the ABCC6 activity by a number of mechanisms. First, it is possible that the mutant protein is mis-localized within the hepatocytes and does not migrate into the appropriate plasma membrane location on the baso-lateral surface of hepatocytes ([@R2]). Alternatively, the protein is appropriately targeted to the correct membrane location but the transporter activity is compromised by inability of the protein to perform its transport function, for example due to deficient binding and hydrolysis of ATP ([@R8]). We first determined the subcellular localization of the human mutant protein expressed from an expression vector under the control of a liver-specific mouse albumin promoter delivered to the mouse liver by hydrodynamic injection through the tail vein ([@R9]). After 3 days of delivery, the livers were harvested, and the subcellular localization of the human as well as endogenous mouse ABCC6 protein was determined by immuno staining with antibodies that differentially recognize human and mouse protein epitopes ([Fig. 2](#F2){ref-type="fig"}). As demonstrated previously, the endogenous mouse ABCC6 protein resides at the baso-lateral surface of the hepatocyte plasma membrane ([@R27]). Similarly, 9 out of the 10 human mutant proteins tested in this study were co-localized with the mouse protein at the proper membrane location ([Fig. 2A](#F2){ref-type="fig"}). However, one mutation, p.L605P, did not allow the protein to migrate to the plasma membrane, and the mutant protein was localized exclusively in the cytoplasm ([Fig. 2A and B](#F2){ref-type="fig"}). Similarly, another, previously identified mutation, p.R1114P, resulted in partial retention of the protein in the cytoplasm while some cells demonstrated plasma membrane staining ([@R2]) ([Fig. 2B](#F2){ref-type="fig"}).

A chaperone compound, 4-phenylbutyrate (4-PBA), has previously been shown to facilitate transfer of some mutant mis-targeted ABCC6 molecules from the cytoplasm to the plasma membrane ([@R2]). Consequently, we tested the effect of 4-PBA on the subcellular localization of the p.L605P and p.R1114P mutants by treating mice with this compound two days prior and four days following the injection of the expression construct for a total of 6 days. 4-PBA clearly facilitated the transfer of the cytoplasmic mutant p.R1114P protein to the plasma membrane, as shown previously ([@R26]) ([Fig. 2B](#F2){ref-type="fig"}). However, this compound had no effect on the subcellular localization of the protein harboring the mutation p.L605P. Thus, 4-PBA may be of help in facilitating the proper targeting of some, but not all, mutant ABCC6 proteins to the plasma membrane.

Demonstration of pathogenicity in zebrafish mRNA rescue assay {#S5}
-------------------------------------------------------------

The pathogenicity of the missense mutations identified in *ABCC6* was further investigated in a zebrafish mRNA rescue assay that we have recently developed ([@R17]; [@R43]). In this assay, zebrafish embryos are injected with an *abcc6a* morpholino which causes knock-down of the corresponding gene expression. As a consequence, the zebrafish embryos develop a profound phenotype consisting of pericardiac edema, stunted growth and curled tail, and the developing embryos die before the age of 7 days post fertilization (dpf) ([Fig. 3](#F3){ref-type="fig"}). This phenotype can be fully rescued by injection of wild-type human *ABCC6* mRNA together with the morpholino ([Fig. 3](#F3){ref-type="fig"}). We consequently injected zebrafish embryos with the morpholino together with human *ABCC6* mRNA harboring missense mutations identified in this study. As a negative control, the morpholino was injected with the human mRNA harboring stop codon mutation p.R1141X. As shown in [Fig. 3](#F3){ref-type="fig"}, this mRNA containing the nonsense mutation did not rescue the phenotype. Injection of mutant mRNAs harboring the missense mutations identified in this study together with the morpholino revealed that 8 out of 9 mutations tested did not provide significant rescue as judged by either morphology of the zebrafish embryos ([Fig. 3](#F3){ref-type="fig"}) or by the percent of lethality ([Table 2](#T2){ref-type="table"}) at 4 dpf, suggesting that they are pathogenic. Only one mutant mRNA, p.R64Q, resulted in rescue comparable to that of the wild-type mRNA ([Fig. 3](#F3){ref-type="fig"} and [Table 2](#T2){ref-type="table"}). However, the corresponding mutation, c.191G→A, was not present in the SNP database, and it is unclear whether this is a pathogenic mutation in the 5 patients with PXE.

Identification of mutations in the *ENPP1* gene {#S6}
-----------------------------------------------

A male patient diagnosed as having PXE by the presence of characteristic cutaneous findings and histopathology of the skin did not reveal the presence of mutations in *ABCC6* ([Fig. 4](#F4){ref-type="fig"}). Careful examination of the patient revealed several unusual features. First, the patient's cutaneous findings had been noted definitely to be present as early as at 8 years of age categorizing him with a diagnosis of pediatric PXE. Furthermore, in addition to characteristic yellowish papules in the axillary fossa, the patient had large areas of hyperpigmented lesions on the trunk, a finding not characteristic of PXE ([Fig. 4A](#F4){ref-type="fig"}). With the notion that mutations have been recently disclosed in the *ENPP1* gene in patients with cutaneous PXE-like lesions ([@R11]; [@R18]), we next sequenced *ENPP1*, which identified 2 heterozygous mutations, p.Y261X and p.S479F, and the parents were heterozygous carriers, respectively ([Fig. 4B and D](#F4){ref-type="fig"}). The nonsense mutation, p.Y261X, has been previously reported ([@R31]). Sequence alignments indicated that serine at the amino acid position 479 is highly conserved during evolution ([Fig. 4C](#F4){ref-type="fig"}). This sequence variant, p.S479F, was not present in the SNP database, and this mutation was predicted to be probably damaging (0.99) and damaging (0), when analyzed by PolyPhen-2 and SIFT programs, respectively. Collectively, the mutation analysis in the Chinese cohort of PXE demonstrated considerable genetic heterogeneity and identified a number of mutations not previously reported in the literature.

DISCUSSION {#S7}
==========

Understanding of the mechanisms leading to aberrant mineralization of connective tissues has been advanced by observations on a group of heritable disorders manifesting with ectopic mineralization. The prototype of such conditions is PXE, an autosomal recessive disorder which affects a number of organs by ectopic mineralization, with primary clinical findings in the skin, the eyes, and the cardiovascular system ([@R21]; [@R39]). PXE is a rare disorder, with an estimated prevalence of \~1:50,000 which would imply that there are \~7,000 to 8,000 affected individuals in the United States, and with the same prevalence as many as 50,000 patients in China. The diagnosis of PXE is made by a combination of clinical findings in the skin and the eyes, supported by histopathologic and molecular diagnostic observations ([@R38]). While the manifestations of PXE are of late onset and the disease progresses slowly, PXE is associated with major clinical complications, including loss of central vision often leading to blindness, and occurrence of catastrophic cardiovascular events, including early myocardial infarcts and strokes. There is a considerable spectrum of phenotypic presentations and severity of the disease: At one end of the spectrum, young patients in their infancy, with considerable vascular involvement, have been diagnosed with PXE-like cutaneous findings, often classified as pediatric PXE ([@R15]; [@R16]). In addition, patients with GACI, typically caused by mutations in the *ENPP1* gene, can demonstrate PXE-like findings, supporting the notion that there is considerable both clinical and genetic overlap between PXE and GACI ([@R23]).

The classic form of PXE is caused by mutations in the *ABCC6* gene, and over 300 distinct mutations have been identified representing well over 1,000 mutant alleles ([@R37]). Among the published mutations, two common recurrent mutations, p.R1141X and del23-29, account for up to 30% of all mutant alleles ([@R25]; [@R37]). Examination of the ancestry and geographic distribution of patients in the *ABCC6* mutation databases reveals that most patients tested are apparently Caucasians from the United States or European countries, and specific reports of mutations in the Italian, French and German cohorts have been published ([@R4]; [@R7]; [@R25]; [@R34]). Examination of the mutation database indicates that the frequent p.R1141X mutation is distributed widely across Europe, while deletion of exons 23-29 (del23-29) is encountered in Northern Europe and in Northern Mediterranean countries ([@R12]). In addition, limited numbers of patients, with specific mutations, have been reported from Greece, Turkey, South Africa and Brazil ([@R1]; [@R6]; [@R12]; [@R13]; [@R29]). There is a striking paucity of mutation reports on individuals of Asian ancestry. Specifically, there are only four distinct mutations reported in Japanese patients with PXE, and in addition, six *ABCC6* sequence variants have been identified as a cause of angioid streaks in Japanese patients, an eye finding often associated with PXE ([@R24]; [@R33]; [@R36]; [@R42]). There is only one *ABCC6* mutation reported in a Chinese patient with PXE ([@R41]).

In the present study, we have clinically examined a cohort of 29 Chinese patients with PXE, and DNA was available to specifically sequence the exons and flanking intronic sequences of *ABCC6* in a subset of 22 patients. Among the 36 sequence variants identified in *ABCC6*, six small insertions or deletions were causing PTCs, five of them being previously unreported. Among the 23 nonsynonymous missense mutations, ten were initially considered potentially pathogenic based on their absence or presence in low frequency (\<1%) in SNP database, and as judged by bioinformatics prediction programs PolyPhen-2 and SIFT to be damaging to the protein function. Among the 10 putative pathogenic missense mutations tested in zebrafish mRNA rescue assay, nine of them did not provide rescue, confirming the pathogenic nature of the amino acid substitutions. Only one of the mutant mRNAs, harboring mutation p.R64Q, was able to rescue the zebrafish phenotype, similar to that of wild-type mRNA. However, this mutation was not present in the SNP database and three of the five patients with this sequence variant had another allelic *ABCC6* mutation. Therefore, it is unclear whether this mutation, p.R64Q, is pathogenic or not. It should be noted that no *ABCC6* or *ENPP1* mutations were found in two patients, and the overall rate of detection of mutations in *ABCC6* and *ENPP1* was 80 percent (35 mutant alleles of a total 44). It should be noted that, the mutation detection strategy utilized PCR amplification of individual exons and flanking intronic sequences. This approach does not detect mutations in the regulatory upstream sequences or in the 3′-UTR, deeper intronic sequences, or large insertions or deletions ([@R25]).

The consequences of missense mutations were also tested *in vivo* in a mouse system which examines the subcellular targeting of the mutant protein in mouse hepatocytes following hydrodynamic delivery of an expression vectors through the tail vein. The wild-type ABCC6 protein localizes to the basolateral surface of hepatocytes, and 9 out of 10 tested missense mutations allowed the protein to target the physiological plasma membrane location. Only one mutation, p.L605P, resulted in cytoplasmic localization of the mutant protein. Previously, the mutant protein harboring p.R1114P mutation has been shown to remain in cytoplasmic localization which could be corrected by treatment with 4-PBA, a chaperone molecule. However, treatment of mice expressing miss-targeted protein with p.L605P mutation did not result from correction of the subcellular localization. Thus, 4-PBA treatment may be applicable for correction of the subcellular localization only to selected mutant ABCC6 proteins with missense mutations.

One of the patients was diagnosed as PXE manifested with somewhat unusual features, including relatively early age at onset and presence of atypical cutaneous findings, such as extensive hyperpigmentation on the trunk, not a characteristic feature of PXE. Analysis of the *ABCC6* gene failed to identify mutations, but subsequent sequencing of the *ENPP1*, typically associated with GACI, revealed the presence of a nonsense mutation, p.Y261X, and a heterozygous missense mutation, p.S479F. The latter mutation is pathogenic, based on its absence from the SNP database, conservation of the serine-479 through evolution from zebrafish to human, and prediction by PolyPhen-2 and SIFT programs as damaging. This previously unreported missense mutation contributes to the growing database of *ENPP1* mutations, and this case also illustrates the phenotypic overlap between PXE and GACI. It should be noted that mutations in the *ENPP1* gene have been recently identified in Cole disease, a rare autosomal dominant genodermatosis featuring punctate keratoderma, patchy hypopigmentation, and uncommonly, cutaneous calcifications ([@R5]). These observations may have relevance to pigmentary changes noted in our patient diagnosed with pediatric PXE.

Collectively, this study identified 16 mutations, 15 of them in *ABCC6* and 1 in *ENPP1*, in the Chinese PXE population, with implications for accurate diagnosis and subclassification. This information can be used for genetic counseling, and it forms the basis for prenatal testing and preimplantation genetic diagnosis in future pregnancies in families at risk for recurrence. Knowledge of the specific mutations can also be used for presymptomatic testing in families with known history of PXE ([@R1]; [@R19]). Important for the patients, identification of the precise nature of the mutations underlying the PXE phenotype provides a basis for development of treatment modalities tailored to be allele specific.

MATERIAL AND METHODS {#S8}
====================

Patient samples {#S9}
---------------

A total of 29 unrelated patients with the putative diagnosis of PXE were investigated. Informed consent was obtained from all subjects, and the present study was approved by the local Medical Research Ethics Committee at Xijing Hospital, Fourth Military Medical University, Xi'an, China. The primary diagnosis of PXE was based on dermatological, ophthalmologic, and/or histopathologic evaluations ([@R38]). In each proband, the skin lesions were histologically confirmed to be consistent with the diagnosis of PXE by the observation of calcified elastic fibers in biopsy specimens upon hematoxylin and eosin, Verhoeff van Gieson and/or von Kossa stains with standard protocols.

Mutation analysis {#S10}
-----------------

Genomic DNA was isolated from peripheral blood leukocytes or paraffin embedded skin tissues from 22 patients from whom samples were available, according to standard procedures. Mutation detection comprised polymerase chain reaction (PCR) amplification of each of the 31 exons in the *ABCC6* gene using primer pairs placed on the flanking intronic sequences ([@R25]). This protocol excludes amplification of the two *ABCC6* pseudogenes with sequences corresponding to the 5′end of *ABCC6* ([@R28]). Purified PCR products were sequenced for variants by comparison with the published cDNA sequence (Gen Bank accession no. NM_001171). The samples in which no mutations were found in the *ABCC6* gene were further analyzed for the *ENPP1* gene using the same strategy. Evolutionary conservation of the amino acid residue serine-479 in *ENPP1* was examined by sequence alignment with Ensemble program.

Mice {#S11}
----

Immunodeficient *Rag1^−/−^* mice in C57/BL6 background (strain: 002216F; Jackson Labs, Bar Harbor, ME), which are wild-type for *Abcc6*, were used in this study. The mice were maintained under standard laboratory conditions and were handled in accordance with the guidelines for animal experiments by the Institutional Animal Care and Use Committee of Thomas Jefferson University.

Reagents, plasmid and site-directed mutagenesis {#S12}
-----------------------------------------------

Sodium 4-phenylbutyrate (4-PBA) was purchased from Sigma-Aldrich (Deisenhofen, Germany) and dissolved in 0.9% NaCl prior to use. A full-length wild-type human *ABCC6* cDNA was cloned into pLIVE^™^ expression vector purchased from Mirus (MIR5420, Madison, WI). Using this cDNA as a template, ten different *ABCC6* missense DNA-constructs were obtained by site-directed mutagenesis following the manufacturer's instructions (Agilent, Santa Clara, CA).

Liver-specific expression of ABCC6 variants in mice {#S13}
---------------------------------------------------

Liver-specific expression of ABCC6 variants was performed in mice as described in our previous studies ([@R9]; [@R10]; [@R26]) Briefly, pLIVE expression vector (Mirus Bio, Madison, WI) containing the wild-type or mutant *ABCC6* was delivered into the mice by hydrodynamic tail-vein injection of 10% body volume of TransIT-QR hydrodynamic delivery solution (Mirus), as recommended by the manufacturer's instructions, using a 26-gauge syringe needle. At least three mice were injected with each form of the human *ABCC6* cDNA. Mice were sacrificed 3--4 days after hydrodynamic tail vein injections and the livers were harvested for immunofluorescence.

4-PBA treatment of mice {#S14}
-----------------------

Mice received intraperitoneal injection of 4-PBA (100 mg/kg per day), once a day for 4 days initiated at the time of hydrodynamic tail-vein injection, and they additionally received an approximate dosage of 1000 mg/kg per day in the drinking water, two days prior and four days following the injection, for a total of 6 days.

Immunofluorescence {#S15}
------------------

Immunofluorescence was performed on 8-μm thick frozen liver sections. Slices were fixed in methanol and then washed with PBS. After incubation in blocking buffer for 13hour, the primary antibody recognizing human ABCC6 protein (M6II-7, 1:100; abcam, Cambridge, MA) was added first for 1 hour, followed by incubation with the primary antibody specific for mouse ABCC6 protein (s-20, 1:200; Santa Cruz, Dallas, Texas) for 13hour. After washing with PBS, the sections were incubated with secondary antibodies for 1 hour and the nuclei were stained with 4′, 6-diamidino-2-phenylindole for 53minutes. The stained samples were analyzed using a fluorescent microscope (Zeiss, Göttingen, Germany).

Zebrafish mRNA rescue assay {#S16}
---------------------------

To test the potential pathogenicity of *ABCC6* missense mutations, a zebrafish mRNA rescue assay was performed as described previously ([@R17]; [@R43]). Briefly, human *ABCC6* variants were cloned in Bluescript II SK- vector, and mRNA was generated by *in vitro* transcription using the mMessage mMachine kit (Ambion, Austin, TX). A morpholino specific for zebrafish *abcc6a* sequence was injected into one- to four-cell-stage embryos either alone or in combination with the human, either mutant or wild-type *ABCC6* mRNA (2.4 mmol). The injected zebrafish embryos were followed for their phenotype and survival rate on daily intervals.

Ethics Statement {#S17}
----------------

Informed written consent was obtained from all subjects, and the present study was approved by the local Medical Research Ethics Committee at Xijing Hospital, Fourth Military Medical University, Xi'an, China.

The mice were maintained under standard laboratory conditions and were handled in accordance with the guidelines for animal experiments by the Institutional Animal Care and Use Committee of Thomas Jefferson University.
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![The positions of *ABCC6* mutations identified in Chinese patients with PXE\
(a) Intron-exon organization of *ABCC6* gene. Vertical boxes represent the 31 exons; Missense mutations are shown above, and insertion or deletion mutations resulting in PTC below the line; Green exons code for the two nucleotide-binding fold domains of the protein; Black, previously reported mutations; Red, to our knowledge previously unreported mutations; \*denotes the presence of the mutation in multiple alleles/patients with the number of affected alleles in parenthesis. (b) Positions of the missense variants in the membrane topology model of the ABCC6 protein. The various protein domains are delineated by horizontal arrows above; the positions of amino acid variants investigated in the study are in red; nucleotide binding fold domains and intracellular loops are colored with gray and blue, respectively.](nihms655431f1){#F1}

![Subcellular localization of human ABCC6 missense variants expressed in mouse liver, and the effect of 4-phenylbutyrate (4-PBA) on their localization\
(a) The human (red) and mouse (green) ABCC6 proteins were detected on frozen sections of mouse liver by immunofluorescence with species specific primary antibodies three days after hydrodynamic tail vein injection of each ABCC6 missense variant in an expression vector. (b) Mice injected with ABCC6 missense variants were treated with (b, right panels) or without (b, left panels) 4-PBA. Scale bar = 100 mm.](nihms655431f2){#F2}

![Morphology of zebrafish 4 days after co-injection of an *ABCC6A* knock-down morpholino together with different human *ABCC6* mRNA variants\
The morpholino-induced phenotype consisting of pericardiac edema, stunted growth and curled tail, similar to zebrafish injected with morpholino (MO) alone, was observed in zebrafish co-injected with human *ABCC6* mRNA carrying p.R1141X, p.P4H, p.A9E, p.P21S, p.R419Q, p.E125K, p.E709G or p.L948P mutation, indicating lack of rescue and implying pathogenicity. Zebrafish co-injected with MO and *ABCC6* mRNA carrying R64Q mutation showed wild-type phenotype, similar to fish injected with MO together with human wild-type (WT) ABCC6 mRNA.](nihms655431f3){#F3}

![Cutaneous presentation, histopathology and mutation detection in a pediatric patient with PXE\
(a) Hyperpigmentation on the trunk (left) and yellowish papules in the axillary fossa (upper right); Aberrant calcification in the dermis detected by von Kossa stain (bottom right); (b) A heterozygous mutation, p.S479F, in the *ENPP1* gene revealed by mutation analysis (arrow); (c) Conservation of the serine-479 during evolution from zebrafish to human (outlined). Scale bar = 100 mm.](nihms655431f4){#F4}

###### 

The missense variants of ABCC6 discovered in 22 Chinese patients with PXE, and bioinformatics predictions of the consequence of the mutations

  Mutations         SIFT[+](#TFN2){ref-type="table-fn"}   PolyPhen2[+](#TFN2){ref-type="table-fn"}   
  ----------------- ------------------------------------- ------------------------------------------ ------------------
  c.1814T\>C        p.Leu605Pro                           Damaging (0)                               Probably (1)
  c.373G\>A         p.Glu125Lys                           Damaging (0.01)                            Probably (0.997)
  c.11C\>A          p.Pro4His                             Damaging (0)                               Probably (0.957)
  c.1256G\>A        p.Arg419Gln                           Damaging (0)                               Probably (0.994)
  c.2843T\>C        p.Leu948Pro                           Damaging (0)                               Probably (0.988)
  c.2126A\>G        p\. Glu709Gly                         Damaging (0)                               Probably (0.916)
                                                                                                     
  c.2501T\>C        p.Met834Thr                           Tolerated (0.28)                           Benign (0.047)
  c.61C\>T          p.pro21Ser                            Tolerated (0.45)                           Benign (0.209)
  c.191G\>A         p.Arg64Gin                            Tolerated (0.21)                           Benign (0.051)
  c.26C\>A          p.Ala9Glu                             Damaging (0.02)                            Benign (0.109)
                                                                                                     
  c.268G\>A         p.Ala90Thr                            Tolerated (0.5)                            Benign (0)
  c.232G\>A (x7)    p.Ala78Thr                            Tolerated (0.18)                           Benign (0.018)
  c.4324G\>A (x2)   p.Arg1442Thr                          Tolerated (0.47)                           Benign (0.188)

The recurrent mutation in multiple alleles is indicated with the number of affected alleles in parentheses.

Indicates the prediction of the consequences of the mutations on the protein function with the score in parentheses.

###### 

Zebrafish mRNA rescue assay

  Group[\*](#TFN3){ref-type="table-fn"}   ABCC6 mRNA variant   No. of embryos injected   Lethality (%)[†](#TFN4){ref-type="table-fn"}
  --------------------------------------- -------------------- ------------------------- ----------------------------------------------
  No injection                            \-                   192                       8.7
  MO alone                                \-                   68                        79.3
  MO+                                     p.R1141X             163                       73.8
  MO+                                     WT                   80                        23.4
  MO+                                     p.P4H                71                        85.9
  MO+                                     p.A9E                94                        83.0
  MO+                                     p.P21S               93                        79.0
  MO+                                     p.R64Q               83                        28.7
  MO+                                     p.E125K              109                       63.2
  MO+                                     p.R419Q              48                        89.1
  MO+                                     p.E709G              64                        65.6
  MO+                                     p.M834T              118                       64.4
  MO+                                     p.L948P              109                       71.1

Zebrafish embryos were injected at day 0 with an *abcc6a* morpholino (MO) alone or with human *ABCC6* mRNA, either wild-type (WT) or harboring different mutations.

The cumulative number of dead embryos at 4 days after injection, expressed as % of the total number of embryos injected.

[^1]: These authors contributed equally to this work.
